December 4, 2017 12:00 pm
Published by jonas
CEO Martin Vidaeus explains about development through toxicology and safety studies. About RP101 RP101 is the company’s main development program... View Article
November 28, 2017 12:00 pm
Published by jonas
Following successfully completed toxicology and safety studies, Redwood Pharma has now started production of the drug RP101 for use in... View Article
November 20, 2017 12:00 pm
Published by jonas
Redwood Pharma AB (publ) announces that the RP101 toxicology studies are now successfully completed. The Company can thereby continue the... View Article
September 20, 2017 12:00 pm
Published by jonas
Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 – 8 to meet and continue discussions with potential... View Article
September 1, 2017 12:00 pm
Published by jonas
Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical... View Article
June 2, 2017 12:00 pm
Published by jonas
Medicines that are used in clinical trials are stringently regulated. Regulated production begins now of the active pharmaceutical ingredient in... View Article
March 15, 2017 12:00 pm
Published by jonas
Redwood Pharma AB (publ) now begins toxicological safety studies for its drug development project RP101. The results will initially be... View Article
March 2, 2017 12:00 pm
Published by jonas
Redwood Pharma’s licensor, Broda Technologies, has been granted an additional patent in the US regarding the IntelliGel drug delivery platform.... View Article
February 15, 2017 12:00 pm
Published by jonas
Redwood Pharma AB (publ), End of Year Report 2016 January – December 2016. The period January 1 – December 31,... View Article
February 13, 2017 12:00 pm
Published by jonas
In preparation for the upcoming pharmaceutical clinical trial of RP101, Redwood Pharma AB (publ) has retained Associate Professor Gerhard Garhöfer... View Article